Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
382,523,969
-
Total 13F shares
-
787,669,463
-
Share change
-
+120,726,169
-
Total reported value
-
$1,933,096,110
-
Put/Call ratio
-
46%
-
Price per share
-
$2.38
-
Number of holders
-
245
-
Value change
-
+$286,080,459
-
Number of buys
-
167
-
Number of sells
-
65
Institutional Holders of RECURSION PHARMACEUTICALS, INC. - Common Stock (DNA) as of Q2 2022
As of 30 Jun 2022,
RECURSION PHARMACEUTICALS, INC. - Common Stock (DNA) was held by
245 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
787,669,463 shares.
The largest 10 holders included
BAILLIE GIFFORD & CO, ARK Investment Management LLC, VANGUARD GROUP INC, GENERAL ATLANTIC, L.P., Anchorage Capital Group, L.L.C., MORGAN STANLEY, BlackRock Inc., VIKING GLOBAL INVESTORS LP, Nikko Asset Management Americas, Inc., and Sumitomo Mitsui Trust Holdings, Inc..
This page lists
245
institutional shareholders reporting positions in this security
for the Q2 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.